Abeona Therapeutics Investor Relations Material
Latest events
Q4 2023
Abeona Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Abeona Therapeutics Inc
Access all reports
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. The company's initial focus is on amyotrophic lateral sclerosis therapy based on the conversion of skin cells into motor neurons. Furthermore, the company is developing TAHO, an attenuated adenovirus that is administered orally, for the treatment of patients who have severe combined immunodeficiency (SCID-X1), a rare genetic disease that causes immune system deficiency and increases susceptibility to infection in early childhood.
Latest articles
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Puig's 2024 IPO: Paco Rabanne, Jean Paul Gaultier, and Beyond
Explore Puig's journey from its 1914 inception to a 2024 IPO, showcasing its growth, strategic acquisitions, and impact in the beauty and fashion industry.
15 Apr 2024
Alphabet's Unstoppable Rise: From Stanford to Global Tech Leader
Discover Alphabet's rise from a university project to a global tech leader, highlighting its growth, diversification, and visionary leadership.
15 Apr 2024
Ticker symbol
Country
🇺🇸 United States